IDEXX Laboratories, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IDXX research report →
Range $700 – $750
Price Chart
About the company
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors.
- CEO
- Michael Erickson
- IPO
- 1991
- Employees
- 11,000
- HQ
- Westbrook, ME, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a long-term uptrend, trading well above its 200-day moving average of 572.35 and 50-day average of 562.41. It is still below the 52-week high of 769.98, keeping the setup constructive but not extended from its broader base.
Street sentiment stays constructive, with a Buy consensus and an average target of 717.17, modestly above the last close. Recent calls have been mixed but still supportive: UBS raised its target to 700, while several firms trimmed targets without turning negative.
IDXX has a perfect 8-for-8 EPS beat streak, including a 7.3% beat last quarter and 8.1% the quarter before. Next-year EPS is still rising to 16.89 from 14.84 TTM, so shareholders should watch whether the company keeps converting revenue growth into another clean beat.
Recent insider activity leans to net selling, but most of the volume came from automatic M-Exempt transactions tied to equity awards and related tax handling. The discretionary signal is lighter: there were several open-market sales by the EVP, GC & Corporate Secretary and the Executive Chair, with no offsetting buys.
Profitability remains elite, with a 32.5% operating margin, 25.4% net margin, and 62.7% gross margin. Revenue grew 9.9% year over year and earnings grew 17.9%, while free cash flow reached $1.31 billion on 2025 results.
IDXX still screens as a premium diagnostics franchise, supported by stronger margins and steadier earnings delivery than most healthcare equipment peers. The valuation is rich at 49.27 times earnings, so the setup favors execution over multiple expansion.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $53.28B
- P/E
- 46.85
- Fwd P/E
- 45.34
- PEG
- 2.69
- P/S
- 11.80
- P/B
- 29.46
- EV/EBITDA
- 33.38
- Div Yield
- 0.00%
- Gross Margin
- 62.72%
- Op Margin
- 32.30%
- Net Margin
- 25.36%
- ROE
- 71.18%
- ROIC
- 39.88%
Latest fiscal year · YoY change
- Revenue
- $4.30B+10.4%
- Gross Profit
- $2.66B+11.8%
- Op Income
- $1.36B
- Net Income
- $1.06B+19.3%
- EPS
- $13.17+22.3%
- OCF Growth
- +27.2%
- FCF Growth
- +32.5%
- 52W High
- $769.98
- 52W Low
- $500.61
- 50D MA
- $576.44
- 200D MA
- $573.32
- Beta
- 1.54
- RSI (14)
- 60
- Avg Volume
- 557.42K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
IDEXX posted a strong Q3 with 10% organic revenue growth, expanding margins, and raised full-year guidance on the back of innovation-led demand and strong execution.· November 2, 2026
- Q3 organic revenue grew 10%, led by 11% organic growth in CAG Diagnostics recurring revenue and 14% organic growth internationally in CAG diagnostics recurring revenue.
- EPS reached $4.01, up 18% as reported and 22% on a comparable basis, while comparable operating margin expanded about 60 basis points year over year.
- Management raised full-year revenue guidance to $4.741 billion-$4.767 billion and EPS guidance to $14.96-$15.16, citing strong Q3 results and about $5 million of CoVet revenue.
- Premium instrument placements were strong at 5,780 units, including 1,904 inVue Dx instruments, and management said the company is on track to exceed its 5,500 inVue placement goal for the year.
- CoVet adds an AI/software growth driver but also introduces near-term dilution and roughly 30 basis points of operating margin impact in 2026.
Reported Q3 revenue growth was 10% organically. CAG Diagnostics recurring revenue grew 11% organically, with about 4% global net price improvement; U.S. organic CAG Diagnostics recurring revenue grew 9.6% and international CAG Diagnostics recurring revenue grew 14%. Gross profit increased 12% as reported and gross margin was 62.9%, up 110 basis points as reported and 90 basis points on a comparable basis. Operating margin was 33.1%, up 100 basis points as reported and about 60 basis points on a comparable basis, and EPS was $4.01, up 18% as reported and 22% on a comparable basis. Free cash flow was $421 million in Q3 and $978 million year to date. For the full year, IDEXX raised revenue guidance to $4.741 billion-$4.767 billion, organic revenue growth to 9.3%-10%, CAG Diagnostics recurring organic growth to 10.3%-11%, and EPS guidance to $14.96-$15.16. Full-year operating margin guidance was raised to 32.1%-32.3%, and the company now expects free cash flow conversion of 95%-100% of net income with capital spending of about $160 million.
Mike Erickson framed the quarter as evidence that IDEXX is in the early innings of a broad innovation cycle, with growth driven by diagnostics, software, and commercial execution. He highlighted inVue Dx, IDEXX Cancer Dx, Catalyst proBNP, and CoVet as connected offerings that expand care and support higher diagnostic utilization. His tone was confident and upbeat, emphasizing that growth is outpacing sector averages and does not depend on improving vet visit counts.
Andrew Emerson emphasized strong operating leverage, with gross margin up to 62.9% and operating margin reaching 33.1% despite CoVet-related costs and ongoing investment. He said free cash flow was $421 million in the quarter, year-to-date free cash flow was $978 million, and trailing-12-month net income to free cash flow conversion was 110%; full-year conversion is now expected at 95%-100% with about $160 million of capital spending. He also noted the balance sheet remains strong, total debt was aligned with prior year-end after repaying $75 million of senior notes, and the company deployed about $335 million toward CoVet and share repurchases in Q3, with $805 million of repurchases year to date and a 2% reduction in diluted shares outstanding.
Analysts focused on why IDEXX can keep raising organic growth guidance despite weak U.S. vet visit trends, and management said growth is being driven by innovation, commercial execution, and higher-quality visits rather than visit volume alone. On inVue Dx, management confirmed it is on track to exceed both the 5,500 annual placement goal and the five-year 20,000 placement goal, and said the platform is still in a worldwide launch phase with additional menu expansion ahead. Questions also centered on 2027 margin implications from CoVet; management said about 30 basis points of margin impact is embedded in 2026, expects to grow into the deal over the next 12 months, and does not see the acquisition changing the long-term operating margin algorithm.
The call showed broad-based demand for IDEXX’s innovation stack, with inVue Dx, Cancer Dx, Catalyst additions, and software all contributing to growth. Management sounded confident that the business can keep growing above sector averages even without a meaningful rebound in visit counts, helped by aging pets, menu expansion, and stronger customer adoption of diagnostics.
Management repeatedly acknowledged that macro conditions and clinical visit trends remain choppy, with U.S. same-store clinical visits down an estimated 1.8% in the quarter and puppy/kitten adoption still muted. CoVet adds near-term dilution and about 30 basis points of operating margin pressure in 2026, and fourth-quarter reported operating margin is expected to be lower at 28.4%-29.3% because of CoVet expenses and ongoing investment.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 78.79M
- Float Shares
- 78.49M
of shares held by institutions
1,335 13F filers
Buy/sell ratio 0.22. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for IDXX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 25, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 4, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Sell | Jan 13, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Sell | Dec 2, 25 | Filing → |
| April McClain DelaneyHouse · MD06 | Sell | Oct 29, 25 | Filing → |
| April McClain DelaneyHouse · MD06 | Sell | Oct 16, 25 | Filing → |
| Byron DonaldsHouse · FL19 | Buy | Sep 4, 25 | Filing → |
| Byron DonaldsHouse · FL19 | Buy | Sep 4, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 5, 25 | Filing → |
| April McClain DelaneyHouse · MD06 | Sell | Aug 7, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 9.95M | ▼ 16.70K |
| Blackrock, Inc. | 8.10M | ▼ 69.96K |
| Vanguard Capital Management LLC | 5.16M | ▲ 4.70K |
| Vanguard Portfolio Management LLC | 3.96M | ▲ 59.41K |
| State Street Corp | 3.76M | ▲ 12.70K |
| Invesco Ltd. | 3.37M | ▼ 237.75K |
| Geode Capital Management, LLC | 2.62M | ▲ 57.82K |
| Bamco Inc | 1.78M | ▼ 194.28K |
| Morgan Stanley | 1.37M | ▲ 18.24K |
| Arrowstreet Capital, Limited Partnership | 1.36M | ▲ 292.35K |
| Goldman Sachs Group Inc | 1.18M | ▲ 437.93K |
| T. Rowe Price Investment Management, Inc. | 1.03M | ▲ 1.03M |
Held by 2,227 ETFs
Biggest fund positions in IDXX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Lane Michael | other | 197 |
| Nov 18, 26 | Lane Michael | other | 183 |
| Nov 18, 26 | Lane Michael | other | 483 |
| Nov 18, 26 | Lane Michael | other | 183 |
| Nov 18, 26 | Lane Michael | other | 483 |
| Nov 18, 26 | Lane Michael | other | 197 |
| Nov 16, 26 | MAZELSKY JONATHAN JAY | other | 700 |
| Nov 10, 26 | FENNELL GEORGE | other | 483 |
| Nov 10, 26 | FENNELL GEORGE | other | 560 |
| Nov 10, 26 | FENNELL GEORGE | other | 706 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IDXX coverage
Recent articles, reports, and earnings notes.

IDEXX Laboratories (IDXX): Premium Diagnostics, Rich Valuation
IDEXX posted double-digit Q3 growth and raised full-year guidance, but the stock already prices in much of that strength. Our stance is Hold with a fair value of $690.

IDEXX Laboratories, Inc. (IDXX) spikes on deep earnings beat
IDEXX Laboratories, Inc. (IDXX) spiked after a strong Q3 beat, margin expansion, and raised 2026 guidance. This deep-dive looks beyond the headline, breaking down recurring diagnostics growth, international momentum, premium instrument placements, cash flow strength, and what the results may mean for the stock.

IDEXX Laboratories, Inc. (IDXX) jumps 19% on earnings
IDEXX Laboratories, Inc. (IDXX) jumps after a strong Q3 report and higher full-year guidance. The veterinary diagnostics leader beat earnings estimates, posted double-digit revenue growth, and raised its 2026 outlook, fueling a sharp revaluation as investors responded to improving fundamentals.
Want a deeper read on IDXX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
3 Stocks Rallying After Strong Q3 Earnings and Raised Guidance
zacks.com · Nov 17
IDEXX Laboratories, Inc. $IDXX Stock Sold by Eurizon Capital SGR S.p.A.
defenseworld.net · Nov 15
Allspring Global Investments Holdings LLC Sells 1,583 Shares of IDEXX Laboratories, Inc. $IDXX
defenseworld.net · Nov 13
IDEXX Laboratories (NASDAQ:IDXX) Stock: Insider Michael Lane Sells 3,979 Shares
defenseworld.net · Nov 7
IDEXX Laboratories (NASDAQ:IDXX) Stock: Insider Sharon Underberg Sells 8,906 Shares
defenseworld.net · Nov 7
3 Reasons Growth Investors Will Love Idexx (IDXX)
zacks.com · Nov 6
IDEXX Laboratories: Great Company, But Too Expensive (Rating Downgrade)
seekingalpha.com · Nov 4
IDEXX Laboratories: Q3 Results Confirm They Are Best-In-Class
seekingalpha.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 17, 2026 · Live quote · Not investment advice